Edition:
United States

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

1.71USD
4:00pm EDT
Change (% chg)

$-0.01 (-0.58%)
Prev Close
$1.72
Open
$1.73
Day's High
$1.76
Day's Low
$1.67
Volume
119,585
Avg. Vol
250,754
52-wk High
$3.31
52-wk Low
$1.30

Latest Key Developments (Source: Significant Developments)

Idera Pharmaceuticals Q3 loss per share $0.10
Friday, 28 Oct 2016 07:30am EDT 

Idera Pharmaceuticals Inc : Idera Pharmaceuticals reports third quarter 2016 financial results . Q3 loss per share $0.10 . Q3 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S . Q3 revenue $300,000 .Q3 revenue view $117,000 -- Thomson Reuters I/B/E/S.  Full Article

Baker Bros. Advisors LP reports 7.2 pct stake in Idera Pharmaceuticals - SEC filing
Tuesday, 11 Oct 2016 05:33pm EDT 

Baker Bros. Advisors LP:Baker Bros. Advisors LP reports 7.2 percent stake in Idera Pharmaceuticals Inc as of Oct. 7 - sec filing.  Full Article

Idera Pharmaceuticals says public offering of 25 mln common shares priced at $2.00 per share
Friday, 7 Oct 2016 09:04am EDT 

Idera Pharmaceuticals Inc : Idera Pharmaceuticals announces pricing of public offering of common stock .Says public offering of 25.0 million common shares priced at $2.00per share.  Full Article

Idera Pharma says announces proposed public offering of common stock
Wednesday, 5 Oct 2016 04:00pm EDT 

Idera Pharmaceuticals : Idera pharmaceuticals inc says intends to offer and sell up to $50,000,000 of shares of its common stock in an underwritten public offering . Idera pharmaceuticals announces proposed public offering of common stock . Idera pharmaceuticals inc says intends to offer and sell up to $50 million of shares of its common stock in an underwritten public offering .Intends to use net proceeds from offering to advance clinical development of certain of its programs.  Full Article

Idera Pharmaceuticals Q2 loss per share $0.11
Tuesday, 2 Aug 2016 07:00am EDT 

Idera Pharmaceuticals Inc : Q2 loss per share $0.11 . Q2 revenue $300,000 . Idera Pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S .Q2 revenue view $142,000 -- Thomson Reuters I/B/E/S.  Full Article

Idera Pharmaceuticals reports Q1 loss per share $0.11
Monday, 9 May 2016 04:00pm EDT 

Idera Pharmaceuticals Inc : Idera pharmaceuticals reports first quarter 2016 financial results and provides corporate update . Q1 loss per share $0.11 .Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.  Full Article

Idera Pharmaceuticals Inc announces initiation of Phase 1/2 Clinical Trial of Intra-tumoral IMO-2125 in Combination With Ipilimumab in Patients With Metastatic Melanoma
Monday, 14 Dec 2015 08:00am EST 

Idera Pharmaceuticals Inc:Commenced enrollment in a Phase 1/2 clinical trial evaluating intra-tumoral IMO-2125, a TLR9 agonist in combination with ipilimumab (an anti-CTLA4 antibody) in patients with previously treated metastatic melanoma.  Full Article

Idera Pharmaceuticals, Inc intent to acquire Embarcadero
Wednesday, 7 Oct 2015 01:00pm EDT 

Idera Pharmaceuticals, Inc:Says agreement to acquire Embarcadero Technologies.Deal is expected to close in mid-Oct.  Full Article

Idera Pharmaceuticals Inc gives new preclinical data for cancer immunotherapy
Wednesday, 16 Sep 2015 09:00am EDT 

Idera Pharmaceuticals Inc:Gives new preclinical data for cancer immunotherapy with intratumoral injections of imo-2125 & in combination with ipilimumab.Says new preclinical data that showed potent and systemic anti-tumor activity in preclinical cancer models.Imo-2125 induces systemic antitumor immune response with potential to sensitize tumor microenvironment.Expects to initiate first clinical study of intratumoral imo-2125 in combination with ipilimumab in Q4.  Full Article

Idera Pharmaceuticals Inc enters into strategic clinical research alliance with MD Anderson Cancer Center
Monday, 8 Jun 2015 08:00am EDT 

Idera Pharmaceuticals Inc:Idera Pharmaceuticals enters into a strategic clinical research alliance with md Anderson cancer center to advance clinical development of intratumoral tlr9 agonist in combination with checkpoint inhibitors.Says first clinical trial of imo-2125 and checkpoint inhibitors to be initiated 2h 2015.Imo-2125 has been evaluated subcutaneously in over 80 human subjects, was well tolerated, was shown to induce immune responses.Intends to submit investigational new drug application for IMO-2125 and initiate clinical study in second half of year.  Full Article

More From Around the Web

BRIEF-Idera Pharmaceuticals reports Q1 loss per share $0.10

* Idera Pharmaceuticals reports first quarter 2017 financial results and provides corporate update